MIRI, SYNA
MIRI, SYNA
Dipartimento di Fisiopatologia Medico-Chirurgica e dei Trapianti
Bortezomib for rituximab-refractory immune-mediated thrombotic thrombocytopenic purpura in the caplacizumab era: an Italian multicenter study
2025 J.A. Giannotta, A. Artoni, I. Mancini, P. Agosti, M. Carpenedo, A. Truma, S. Miri, B. Ferrari, P. De Leo, P. Salutari, G. Mancini, A. Molteni, E. Rinaldi, M. Bocchia, M. Napolitano, L. Prezioso, A. Cuccaro, E. Scarpa, A. Condorelli, D. Grimaldi, M. Massaia, F. Peyvandi
Inhibitor development upon switching from plasma-derived to recombinant factor VIII in previously untreated patients with severe hemophilia A: the PUP-SWITCH study
2024 S. Miri, F.R. Rosendaal, K. Kavakli, P. Eshghi, S.M. Moghaddam, S. Scardo, B. Habibpanah, M. Elalfy, S. Halimeh, G. Nicolò, D. Gökçebay, N. Özbek, T. Celkan, A. Mohammadi, M. Karimi, A. Shahsavani, B. Yılmaz, C. Albayrak, B. Gunes, Z. Kaya, Y. Ay, S. Akbayram, N. Sarper, P.M. Mannucci, F. Peyvandi
PHD / DOTTORATO
2023 S. Miri
Immune Responses to Plasma-Derived Versus Recombinant FVIII Products
2021 F. Peyvandi, S. Miri, I. Garagiola
IgG subclasses as biomarkers for persistence of factor VIII inhibitors in previously untreated patients with severe haemophilia A
2020 F. Peyvandi, S. Miri, P. Bucciarelli, C. Valsecchi, L. Schiavone, M. Boscarino, R. Palla, P.M. Mannucci, F.R. Rosendaal